Finance

Lists
Why is MANKIND down 3,07%?
Dive Deeper
MANKIND:NSE
Mankind Pharma Ltd
2 275,50 INR
-3,07%
(-72,10) 1D
16 ოქტ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for MANKIND...
Open
2 349,90 INR
High
2 354,40 INR
Low
2 268,70 INR
Mkt. cap
937,40 მლრ.
Avg. vol.
483,95 ათ.
Volume
889,73 ათ.
P/E ratio
46,04
52-wk high
2 642,00 INR
52-wk low
1 909,70 INR
EPS
49,42 INR
No. of employees
20 ათ.
Open
2 349,90 INR
High
2 354,40 INR
Low
2 268,70 INR
Mkt. cap
937,40 მლრ.
Avg. vol.
483,95 ათ.
Volume
889,73 ათ.
P/E ratio
46,04
52-wk high
2 642,00 INR
52-wk low
1 909,70 INR
EPS
49,42 INR
No. of employees
20 ათ.
News stories
From web sources and news partners
Profile
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
About Mankind Pharma Ltd
CEOრაჯივ ჯუნეა | შიტალ არორა
Employees20,5 ათ.
Founded1991
Headquarters-
SectorPharmaceutical industry
Websitemankindpharma.com
Next call 8 დღეში
ორშ, 26 ოქტ, 14:30
Fiscal period
Q2 2027
- / 14,77 INR
Revenue / Est. (INR)
- / 41,66 მლრდ.
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
36,97 მლრდ.
35,67 მლრდ.
34,43 მლრდ.
40,31 მლრდ.
Cost of goods sold
10,62 მლრდ.
9,78 მლრდ.
11,71 მლრდ.
10,98 მლრდ.
Cost of revenue
10,62 მლრდ.
9,78 მლრდ.
11,71 მლრდ.
10,98 მლრდ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8,25 მლრდ.
8,24 მლრდ.
15,80 მლრდ.
9,14 მლრდ.
Operating expense
19,35 მლრდ.
18,92 მლრდ.
14,77 მლრდ.
21,02 მლრდ.
Total operating expenses
29,98 მლრდ.
28,70 მლრდ.
26,48 მლრდ.
32,00 მლრდ.
Operating income
7,00 მლრდ.
6,97 მლრდ.
7,95 მლრდ.
8,30 მლრდ.
Other non operating income
918,70 მლნ.
727,50 მლნ.
-2,31 მლრდ.
450,00 მლნ.
EBT including unusual items
6,24 მლრდ.
5,09 მლრდ.
6,59 მლრდ.
7,69 მლრდ.
EBT excluding unusual items
6,24 მლრდ.
6,16 მლრდ.
5,59 მლრდ.
7,69 მლრდ.
Income tax expense
1,04 მლრდ.
951,20 მლნ.
997,50 მლნ.
1,95 მლრდ.
Effective tax rate
16,64%
18,69%
15,13%
25,39%
Other operating expenses
8,88 მლრდ.
8,46 მლრდ.
-3,26 მლრდ.
9,63 მლრდ.
Net income
5,12 მლრდ.
4,09 მლრდ.
5,54 მლრდ.
5,68 მლრდ.
Net profit margin
13,84%
11,46%
16,10%
14,09%
Earnings per share
12,38
11,99
13,89
13,74
Interest and investment income
-
-
580,50 მლნ.
-
Interest expense
-1,70 მლრდ.
-1,57 მლრდ.
-1,36 მლრდ.
-1,10 მლრდ.
Net interest expenses
-1,70 მლრდ.
-1,57 მლრდ.
-778,20 მლნ.
-1,10 მლრდ.
Depreciation and amortization charges
2,22 მლრდ.
2,23 მლრდ.
2,23 მლრდ.
2,26 მლრდ.
EBITDA
9,20 მლრდ.
8,42 მლრდ.
9,97 მლრდ.
10,33 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები